Home » Stocks » MOR

MorphoSys AG (MOR)

Stock Price: $20.91 USD 0.57 (2.80%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 2.64B
Revenue (ttm) 123.67M
Net Income (ttm) -176.57M
Shares Out 131.04M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $20.91
Previous Close $20.34
Change ($) 0.57
Change (%) 2.80%
Day's Open 20.22
Day's Range 20.15 - 21.03
Day's Volume 38,796
52-Week Range 19.75 - 35.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal ...

Other stocks mentioned: INCY
5 days ago - Accesswire

MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in Englis...

1 week ago - Accesswire

Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stag...

2 weeks ago - Accesswire

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Other stocks mentioned: INCY
3 weeks ago - Zacks Investment Research

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first pa...

Other stocks mentioned: INCY
3 weeks ago - Accesswire

PLANEGG, BAVARIA / ACCESSWIRE / March 15, 2021 / Conference call and webcast (in English) tomorrow, March 16, 2021 at 2:00pm CET (1:00pm GMT/9:00am EDT) MorphoSys AG (FSE:MOR; Prime Standard Segment; MD...

2 months ago - Accesswire

Conference Call Alert PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 9, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and...

2 months ago - Accesswire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 2, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, p...

2 months ago - Accesswire

PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 01, 2021 / MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDA...

2 months ago - Accesswire

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health ...

Other stocks mentioned: INCY
4 months ago - Accesswire

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in anti...

4 months ago - Accesswire

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody,...

4 months ago - Accesswire

High-Yield equity REITs have regularly underperformed. We expect that trend to continue over the next decadeREITs with high yields, low FFO multiples, and weak balance sheets have regularly underperformed.

Other stocks mentioned: KBWY, PFF, VNQ
4 months ago - Seeking Alpha

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2021 as follows:   Publication of I...

4 months ago - Accesswire

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Other stocks mentioned: INCY
6 months ago - Zacks Investment Research

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INC...

Other stocks mentioned: INCY, XNCR
6 months ago - Business Wire

Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

Other stocks mentioned: INCY
7 months ago - Business Wire

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

9 months ago - Seeking Alpha

Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

Other stocks mentioned: HELE, PFSI, TPL
10 months ago - Zacks Investment Research

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Other stocks mentioned: INCY
11 months ago - Zacks Investment Research

MorphoSys AG (MPSYF) CEO Jean Kress on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.

Other stocks mentioned: INCY
1 year ago - The Motley Fool

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.

1 year ago - Zacks Investment Research

MorphoSys AG's (MOR) CEO Simon Moroney on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About MOR

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; G... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 1999
CEO
Jean-Paul Kress
Employees
615
Stock Exchange
NASDAQ
Ticker Symbol
MOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MorphoSys stock is "Buy." The 12-month stock price forecast is 29.83, which is an increase of 42.66% from the latest price.

Price Target
$29.83
(42.66% upside)
Analyst Consensus: Buy